What changed in ICON plc's latest annual report
In the year ended 31 Dec 2025, ICON plc's revenue rose 0.8% to USD 8.25bn, from USD 8.19bn; net income fell 69% to USD 229.34m, from USD 739.13m; cash and cash equivalents rose 20.1% to USD 647.29m, from USD 538.78m.
Year ended 31 Dec 2025. Source: 20-F filed 27 May 2026, read it on SEC EDGAR.
USD 8.19bn to USD 8.25bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 8.19bn | 8.25bn | Up 0.8% |
| Net income | 739.13m | 229.34m | Down 69% |
| Total assets | 16.63bn | 16.27bn | Down 2.2% |
| Total liabilities | 7.19bn | 7.08bn | Down 1.6% |
| Long-term debt | 3.40bn | 2.87bn | Down 15.4% |
| Cash and cash equivalents | 538.78m | 647.29m | Up 20.1% |
| Shareholders' equity | 9.44bn | 9.19bn | Down 2.6% |
Questions people ask
Did ICON plc's revenue grow last year?
Revenue grew 0.8%, from USD 8.19bn to USD 8.25bn in the year ended 31 Dec 2025.
Is ICON plc profitable?
Yes. Net income was USD 229.34m in the year ended 31 Dec 2025. The year before: USD 739.13m.
How much cash and debt does ICON plc have?
At its latest year end (31 Dec 2025), ICON plc reported cash and cash equivalents of USD 647.29m and long-term debt of USD 2.87bn.
Where do these numbers come from?
From ICON plc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with ICON plc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc.Cash and cash equivalents up 16.3%
- Incyte CorporationNet income up 3845%
- Medpace Holdings, Inc.Shareholders' equity down 44.4%
- Charles River Laboratories International, Inc.Cash and cash equivalents up 9.8%